Director, Business Unit Head, Skeletal Conditions – Brazil

BioMarin is a leading rare disease biotechnology company focused on genetically defined conditions. Guided by our purpose to develop medicines that make a profound impact on people’s lives, our global teams have delivered a portfolio of therapies since our founding in 1997. Our revolutionary treatments for conditions like achondroplasia (the most common form of dwarfism), PKU (phenylketonuria), CLN2, a form of Batten disease, and a number of forms of MPS (mucopolysaccharidosis) offer new possibilities for patients and families who previously had few, if any, available options. More recently, with the close of the Amicus acquisition, our portfolio has expanded to include therapies for Fabry disease and Pompe disease, expanding our ability to reach more people living with rare genetic conditions. Our success comes from our unwavering commitment to excellence, our deep understanding of patient needs, our scientific expertise, and our world-class manufacturing capabilities. At the heart of BioMarin is a dedicated team of the brightest minds in the industry working together to deliver innovative therapies to patients and families around the world. About Commercial Be part of the worldwide infrastructure that gets our drugs to underserved patients around the world. Our global sales force solidifies BioMarin’s commercial presence in the United States and Europe and is rapidly growing in other regions, such as South America, EuMEA, and Asia-Pacific.

The main objective of the Business Unit Head, Skeletal Conditions – Brazil is to lead BioMarin’s Skeletal Conditions (SC) business across the vosoritide (Voxzogo) portfolio, ensuring the right strategies are in place at each stage of product evolution and in close collaboration with regional and global brand teams. For achondroplasia (ACH), the product is currently in the market-access-building phase, so the role must secure sustainable public and private reimbursement pathways and expand the diagnosis-to-treatment ecosystem. In parallel, the role leads the launch of vosoritide for hypochondroplasia (HCH), driving launch excellence and market shaping for the new indication. A central mandate is to anticipate and outperform emerging competition for vosoritide – including novel agents in clinical development for achondroplasia – through distinctive positioning and differentiated scientific and value messaging. The role designs a clear marketing and access strategy, fully understands the customer, and ensures flawless field-force execution, with a Marketing leader reporting into the position and direct leadership of the field team. The Business Unit Head is accountable for growth and margin targets, as defined by the budget process, and for taking the SC team of BioMarin Brazil to new heights through a collaborative yet results-oriented approach.

Lead BioMarin’s Skeletal Conditions (SC) business in Brazil across the vosoritide (Voxzogo) portfolio – achondroplasia (ACH) and the new hypochondroplasia (HCH) indication. The role carries two complementary dimensions: (1) responsibility over the business strategy and results; and (2) responsibility over the team – marketing, through a Marketing leader, and the field/sales team, directly. 1. Strategy & Business Performance (responsibility over the strategy and results) Own the overall commercial strategy for the SC portfolio (ACH and HCH), aligning local execution with regional and global brand strategy. Ensure the market-access pathway for achondroplasia (ACH): as the product is in the access-building phase, secure sustainable public and private reimbursement (navigating ANVISA registration, CONITEC/SUS incorporation, ANS and private payers, CMED pricing and the judicial-access landscape) and strengthen the diagnosis-to-treatment ecosystem. Lead the launch of vosoritide for hypochondroplasia (HCH): drive launch excellence and market shaping for the new indication – building disease